Equity Investments at a Premium in Biotech Licensings
Alliance Watch focuses on alliances between established drug firms and public biotechs in which the larger partner bought equity at a premium to the company's average trading price for the 10 days prior to the deal's announcement.
You may also be interested in...
Unique Device Identification (UDI) is key to better transparency and traceability in the EU. But UDI is new to medtech manufacturers and complex. The commission has published some helpful pointers.
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.